Oruka Therapeutics Secures Major Financing
Oruka Therapeutics, Inc. (NASDAQ: ORKA), based in Menlo Park, California, has announced a significant private placement that is set to bolster its financial resources greatly. The biotechnology firm is dedicated to developing innovative biologics that aim to redefine treatments for chronic skin disorders such as plaque psoriasis. This financing agreement is projected to generate nearly $180 million in gross proceeds for the company.
Details of the Private Placement
The agreement involves Oruka selling approximately 10,933,405 shares of its common stock at a price of $15.00 per share. Additionally, the firm will issue pre-funded warrants for 1,066,666 shares of common stock, priced at $14.999 each. The pre-funded warrants have a nominal exercise price of $0.001. Once this transaction concludes, Oruka expects to have about 67.1 million shares of common stock and equivalents outstanding, reflecting a healthy capital structure.
Use of Proceeds
The funds obtained from this financing will primarily support critical areas, including research and development efforts, management of general corporate expenditures, and meeting working capital requirements. Oruka anticipates that this influx of cash will sustain its operational activities for at least another year, especially following anticipated data readouts from the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b clinical trials planned for 2027.
Key Players in the Financing
This substantial financing round has attracted notable investors, significantly led by Viking Global Investors, along with participation from existing and new investors like Affinity Healthcare Fund and Blackstone Multi-Asset Investing. The transaction is being facilitated by Jefferies, TD Cowen, Guggenheim Securities, and LifeSci Capital, who are acting as joint placement agents.
About Oruka Therapeutics
Founded with the vision of transforming therapies for chronic skin conditions, Oruka Therapeutics is at the forefront of biologic drug development. The company aims to offer effective solutions that allow patients with chronic skin ailments, such as plaque psoriasis, to achieve impressive clearance rates, with administration occurring as seldom as once or twice annually. Oruka is advancing a unique portfolio of engineered antibodies that target the fundamental mechanisms of these skin disorders.
Frequently Asked Questions
What is the main focus of Oruka Therapeutics?
Oruka Therapeutics is focused on developing innovative biologics aimed at treating chronic skin diseases, particularly plaque psoriasis.
How much funding did Oruka Therapeutics secure in this placement?
The company announced a private placement expected to yield approximately $180 million in gross proceeds.
What are the plans for the funds raised?
The proceeds will be used for research and development, general corporate expenses, and working capital needs to support the company's growth.
Who are the main investors in this financing?
Viking Global Investors is leading the financing round, with contributions from both new and existing investors.
What is the goal for Oruka's treatment approaches?
Oruka aims to achieve high rates of disease clearance for patients suffering from chronic skin diseases with significantly less frequent dosing schedules.
